Breton M Asken, Wei-En Wang, Franchesca Arias, Shellie-Anne Levy, Warren W Barker, Monica Rosselli, Rosie Curiel Cid, Michael Marsiske, Melissa J Armstrong, David E Vaillancourt, David A Loewenstein, Glenn E Smith, Ranjan Duara
{"title":"性别和种族在早发性阿尔茨海默病生物标志物和全球功能中的作用。","authors":"Breton M Asken, Wei-En Wang, Franchesca Arias, Shellie-Anne Levy, Warren W Barker, Monica Rosselli, Rosie Curiel Cid, Michael Marsiske, Melissa J Armstrong, David E Vaillancourt, David A Loewenstein, Glenn E Smith, Ranjan Duara","doi":"10.1002/dad2.70157","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Early-onset Alzheimer's disease (EOAD) may have distinct biomarker and clinical features from late-onset AD (LOAD). EOAD is understudied in ethnically heterogeneous populations.</p><p><strong>Methods: </strong>We studied EOAD (<i>N</i> = 44, age 64.7 ± 5.5, 55% female, 52% Hispanic/Latino), LOAD (<i>N</i> = 113), early-onset non-AD (EOnonAD, <i>N</i> = 114), and clinically normal (CN, <i>N</i> = 93) individuals from the 1Florida Alzheimer's Disease Research Center. Group differences and demographic interactions were evaluated in plasma (phosphorylated tau217, glial fibrillary acidic protein, neurofilament light chain), neuroimaging (amyloid positron emission tomography, brain magnetic resonance imaging), and global function (Mini-Mental State Examination, Clinical Dementia Rating Sum of Boxes).</p><p><strong>Results: </strong>AD-related biomarkers and global function were consistently worse in EOAD than EOnonAD and CN, and similar or worse than LOAD. Among EOAD, younger age related to greater amyloid burden among non-Hispanic/Latino individuals only. AD-related biomarker changes were more severe in females than males among non-Hispanic/Latino EOAD, but more severe among males in Hispanic/Latino EOAD.</p><p><strong>Discussion: </strong>The biological and clinical features of EOAD may differ by sex and ethnicity.</p><p><strong>Highlights: </strong>Alzheimer's disease (AD) biomarkers and global functional measures were measured in Hispanic and non-Hispanic individuals with early-onset AD (EOAD).Overall, AD-related biomarkers and global function were consistently worse in EOAD than non-AD cognitive decline and controls, and similar or worse than late-onset AD.Younger age related to greater amyloid burden among non-Hispanic EOAD, but not Hispanic EOAD.Hispanic EOAD males had more severe changes than females, contrasting findings in non-Hispanic EOAD (females more severe than males).</p>","PeriodicalId":53226,"journal":{"name":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","volume":"17 3","pages":"e70157"},"PeriodicalIF":4.4000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340424/pdf/","citationCount":"0","resultStr":"{\"title\":\"Sex and ethnicity in early-onset Alzheimer's disease biomarkers and global function.\",\"authors\":\"Breton M Asken, Wei-En Wang, Franchesca Arias, Shellie-Anne Levy, Warren W Barker, Monica Rosselli, Rosie Curiel Cid, Michael Marsiske, Melissa J Armstrong, David E Vaillancourt, David A Loewenstein, Glenn E Smith, Ranjan Duara\",\"doi\":\"10.1002/dad2.70157\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Early-onset Alzheimer's disease (EOAD) may have distinct biomarker and clinical features from late-onset AD (LOAD). EOAD is understudied in ethnically heterogeneous populations.</p><p><strong>Methods: </strong>We studied EOAD (<i>N</i> = 44, age 64.7 ± 5.5, 55% female, 52% Hispanic/Latino), LOAD (<i>N</i> = 113), early-onset non-AD (EOnonAD, <i>N</i> = 114), and clinically normal (CN, <i>N</i> = 93) individuals from the 1Florida Alzheimer's Disease Research Center. Group differences and demographic interactions were evaluated in plasma (phosphorylated tau217, glial fibrillary acidic protein, neurofilament light chain), neuroimaging (amyloid positron emission tomography, brain magnetic resonance imaging), and global function (Mini-Mental State Examination, Clinical Dementia Rating Sum of Boxes).</p><p><strong>Results: </strong>AD-related biomarkers and global function were consistently worse in EOAD than EOnonAD and CN, and similar or worse than LOAD. Among EOAD, younger age related to greater amyloid burden among non-Hispanic/Latino individuals only. AD-related biomarker changes were more severe in females than males among non-Hispanic/Latino EOAD, but more severe among males in Hispanic/Latino EOAD.</p><p><strong>Discussion: </strong>The biological and clinical features of EOAD may differ by sex and ethnicity.</p><p><strong>Highlights: </strong>Alzheimer's disease (AD) biomarkers and global functional measures were measured in Hispanic and non-Hispanic individuals with early-onset AD (EOAD).Overall, AD-related biomarkers and global function were consistently worse in EOAD than non-AD cognitive decline and controls, and similar or worse than late-onset AD.Younger age related to greater amyloid burden among non-Hispanic EOAD, but not Hispanic EOAD.Hispanic EOAD males had more severe changes than females, contrasting findings in non-Hispanic EOAD (females more severe than males).</p>\",\"PeriodicalId\":53226,\"journal\":{\"name\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"volume\":\"17 3\",\"pages\":\"e70157\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12340424/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/dad2.70157\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Diagnosis, Assessment and Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.70157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
早发性阿尔茨海默病（EOAD）可能与晚发性阿尔茨海默病（LOAD）具有不同的生物标志物和临床特征。EOAD在种族异质性人群中的研究尚不充分。方法：我们研究了来自佛罗里达州阿尔茨海默病研究中心的EOAD （N = 44，年龄64.7±5.5,55%为女性，52%为西班牙裔/拉丁裔）、LOAD （N = 113）、早发性非ad （EOnonAD, N = 114）和临床正常（CN, N = 93）个体。在血浆（磷酸化tau217、胶质纤维酸性蛋白、神经丝轻链）、神经影像学（淀粉样正电子发射断层扫描、脑磁共振成像）和整体功能（迷你精神状态检查、临床痴呆评分方框总和）方面评估组间差异和人口统计学相互作用。结果：ad相关的生物标志物和整体功能在EOAD中始终比EOnonAD和CN差，与LOAD相似或更差。在EOAD中，只有非西班牙裔/拉丁裔个体的年龄越小，淀粉样蛋白负担越大。在非西班牙裔/拉丁裔EOAD中，ad相关生物标志物的变化在女性中比男性更严重，但在西班牙裔/拉丁裔EOAD中，男性更严重。讨论：EOAD的生物学和临床特征可能因性别和种族而异。重点：对西班牙裔和非西班牙裔早发性AD （EOAD）患者进行了阿尔茨海默病（AD）生物标志物和整体功能测量。总体而言，AD相关的生物标志物和整体功能在AD患者中一直比非AD患者认知能力下降和控制更差，与晚发性AD相似或更差。年龄越小，非西班牙裔EOAD患者淀粉样蛋白负担越大，而西班牙裔EOAD患者淀粉样蛋白负担越大。西班牙裔EOAD男性的变化比女性更严重，与非西班牙裔EOAD相比（女性比男性更严重）。
Sex and ethnicity in early-onset Alzheimer's disease biomarkers and global function.
Introduction: Early-onset Alzheimer's disease (EOAD) may have distinct biomarker and clinical features from late-onset AD (LOAD). EOAD is understudied in ethnically heterogeneous populations.
Methods: We studied EOAD (N = 44, age 64.7 ± 5.5, 55% female, 52% Hispanic/Latino), LOAD (N = 113), early-onset non-AD (EOnonAD, N = 114), and clinically normal (CN, N = 93) individuals from the 1Florida Alzheimer's Disease Research Center. Group differences and demographic interactions were evaluated in plasma (phosphorylated tau217, glial fibrillary acidic protein, neurofilament light chain), neuroimaging (amyloid positron emission tomography, brain magnetic resonance imaging), and global function (Mini-Mental State Examination, Clinical Dementia Rating Sum of Boxes).
Results: AD-related biomarkers and global function were consistently worse in EOAD than EOnonAD and CN, and similar or worse than LOAD. Among EOAD, younger age related to greater amyloid burden among non-Hispanic/Latino individuals only. AD-related biomarker changes were more severe in females than males among non-Hispanic/Latino EOAD, but more severe among males in Hispanic/Latino EOAD.
Discussion: The biological and clinical features of EOAD may differ by sex and ethnicity.
Highlights: Alzheimer's disease (AD) biomarkers and global functional measures were measured in Hispanic and non-Hispanic individuals with early-onset AD (EOAD).Overall, AD-related biomarkers and global function were consistently worse in EOAD than non-AD cognitive decline and controls, and similar or worse than late-onset AD.Younger age related to greater amyloid burden among non-Hispanic EOAD, but not Hispanic EOAD.Hispanic EOAD males had more severe changes than females, contrasting findings in non-Hispanic EOAD (females more severe than males).
期刊介绍：
Alzheimer''s & Dementia: Diagnosis, Assessment & Disease Monitoring (DADM) is an open access, peer-reviewed, journal from the Alzheimer''s Association® that will publish new research that reports the discovery, development and validation of instruments, technologies, algorithms, and innovative processes. Papers will cover a range of topics interested in the early and accurate detection of individuals with memory complaints and/or among asymptomatic individuals at elevated risk for various forms of memory disorders. The expectation for published papers will be to translate fundamental knowledge about the neurobiology of the disease into practical reports that describe both the conceptual and methodological aspects of the submitted scientific inquiry. Published topics will explore the development of biomarkers, surrogate markers, and conceptual/methodological challenges. Publication priority will be given to papers that 1) describe putative surrogate markers that accurately track disease progression, 2) biomarkers that fulfill international regulatory requirements, 3) reports from large, well-characterized population-based cohorts that comprise the heterogeneity and diversity of asymptomatic individuals and 4) algorithmic development that considers multi-marker arrays (e.g., integrated-omics, genetics, biofluids, imaging, etc.) and advanced computational analytics and technologies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
